9th 3D Tissue Models Summit 2024

The FDA Modernization Act 2.0 has triggered a new mindset for pharma, with Roche launching the Institute of Human Biology to create better models, and MSD collaborating with Inventia to bioprint 3D in vitro models to screen for neurodegenerative therapeutic candidates.

It has never been a more exciting time to bet on 3D tissue models as the future of drug development, as more and more complex in vitro models undergo validation. However, the big question of "when can we have the confidence in standalone 3D models, and how to do it at scale?" persists.

Making its timely return to Boston this May, the 9th 3D Tissue Models Summit will enable you and your team to uncover best practices across 23+ real-world applications of complex in vitro models across drug discovery and development. Join us to learn from and meet the 'front-line' experts optimizing and leveraging advanced 3D models to confidently empower your own drug development workflows.


URLs:
Website: https://go.evvnt.com/2224592-0?pid=10018
Tickets: https://go.evvnt.com/2224592-2?pid=10018
Brochure: https://go.evvnt.com/2224592-3?pid=10018

Prices:
Full Access Pass: Conference + 3 Workshops - Drug Developer Pricing: USD 4197.00,
Conference + 2 Workshops - Drug Developer Pricing: USD 3797.00,
Conference + 1 Workshop - Drug Developer Pricing: USD 3398.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Full Access Pass: Conference + 3 Workshops - Solution Provider Pricing: USD 5097.00,
Conference + 2 Workshops - Solution Provider Pricing: USD 4631.00,
Conference + 1 Workshop - Solution Provider Pricing: USD 4166.00,
Conference Only - Solution Provider Pricing: USD 3699.00,
Full Access Pass: Conference + 3 Workshops - Academic Pricing: USD 3597.00,
Conference + 2 Workshops - Academic Pricing: USD 3264.00

Speakers: Anastasia Korolj, PhD, Chemical and Biomedical Engineer, Harvard medical school/Massachusetts General Hospital, Beth Hoffman, Chief Executive Officer, Origami Therapeutics, Inc., Bihui Melidosian, Senior Research Investigator, Incyte Corporation, Cindy Cheng, Senior Director - Conjugation and In vitro Evaluation, Eisai, Colin Choi, Associate Scientific Director, Biogen, David Zhang, Head of Bioengineering, ODDITY LABS, Iosif (Sifis) Pediaditakis, Associate Director of Neuroscience, Alchemab, Jason Ekert, Head of US Discovery Translational Technology, UCB S.A., Julia Ramirez-Moya, Scientist, Alnylam Pharmaceuticals, Katia Karalis, Executive Director, Research and Development, Head of Human Systems for Disease Modeling, Regeneron Pharmaceuticals Inc, Louise Ramos, Scientist Rakovina Therapeutics, Inc., Manti Guha, Principal Investigator and CIVM Lead, Incyte Corporation, Max Friesen, Postdoctoral Associate, Whitehead MIT, Muriel Lize, Associate Director, in vitro Respiratory Research, Boehringer Ingelheim, Nicole Kelly, Scientist, Enanta Pharmaceuticals, Richard Cheng, Senior Specialist, Engineer, Merck and Co, Sai Pavan Grandhi, Principal Scientist, Complex In Vitro Models, GlaxoSmithKline Plc, Seongmoon Cheong, Senior Scientist I, Dicerna, Serah Kang, Principal Scientist, Genentech, Simone Romoli, Principal Scientist, Pfizer, Tim Spicer, Director of HTS and Discovery Biology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology